H μυοκαρδίτιδα ως παρενέργεια της αντινεοπλασματικής θεραπείας με αναστολείς σημείων ελέγχου του ανοσοποι-ητικού συστήματος

  • Αντώνιος Γεωργίου Μασδράκης Β`Καρδιολογική Κλινική, Νοσοκομείο ΥΓΕΙΑ, Αθήνα
  • Luigi Coletti Β'` Καρδιολογική Κλινική, Νοσοκομείο ΥΓΕΙΑ, Αθήνα
  • Δημήτριος Ευσταθίου Β`' Καρδιολογική Κλινική, Νοσοκομείο ΥΓΕΙΑ, Αθήνα
  • Στυλιανός Κωνσταντινίδης B' Kαρδιολογική Κλινική, Νοσοκομείο ΥΓΕΙΑ, Αθήνα

Περίληψη

MYOCARDITIS AS A SIDE EFFECT OF ANTI-CANCER THERAPY WITH IMMUNE CHECKPOINT INHIBITORS


Antonios Masdrakis, Dimitrios Efstathiou, Stylianos Konstantinidis


2nd Cardiology Department, Hygeia Hospital, Athens, Greece


Immune Checkpoint Inhibitors (ICI) consist  a new class of anti-cancer drugs which has been developed  in recent years and  shown remarkable results in the fight against metastatic cancers such as melanoma, non-small cell lung cancer and kidney cancer. It is a form of immunotherapy and their mechanism of action lies in the inhibition of "checkpoints" of the immune system used by cancer cells so as not to be neutralized by the natural immune mechanisms of the human body and in particular the T cells. These drugs  boost the immune response against cancer cells, but this reaction also targets the patient's own organs, resulting in the possibility of presentation of immune-related adverse events ("irAEs") which may complicate the administered immunotherapy and lead to its discontinuation. Theoretically any organ can be affected, but more often clinicians  deal with side effects from the gastrointestinal tract, endocrine glands, skin and liver. Cardiovascular side effects are uncommon including myocardits which is the most severe and potentially fatal and other such as Takotsubo syndrome, pericarditis, coronary vasospasm, acute coronary syndrome,vasculitis, arrhythmias and non-inflammatory dysfunction of left ventricle .


Key words: Myocarditis, Immune Checkpoint Inhibitors, Cardiotoxicity, Side effects, T-lymphocytes

Δημοσιευμένα
2020-12-29
How to Cite
ΜΑΣΔΡΆΚΗΣ, Αντώνιος Γεωργίου et al. H μυοκαρδίτιδα ως παρενέργεια της αντινεοπλασματικής θεραπείας με αναστολείς σημείων ελέγχου του ανοσοποι-ητικού συστήματος. hellenicjcardiol, [S.l.], v. 61, n. 5, p. 338-356, dec. 2020. Available at: <http://hellenicjcardiol-gr.gr/index.php/hjc/article/view/340>. Date accessed: 11 may 2021.
Ενότητα
ΑΡΘΡΟ ΑΝΑΣΚΟΠΗΣΗΣ